Clinical features and diagnosis for Chinese cases with malignant hyperthermia: A case cluster from 2005 to 2007

Chinese Medical Journal

Volumn 123, Issue 10, 2010, Pages 1241-1245

  Wang, Ying Lin ^a   Luo, Ai Lun ^b   Tan, Gang ^b   Cui, Xu Lei ^b   Guo, Xiang Yang ^c  

^a HEBEI MEDICAL UNIVERSITY   (China)

^b PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^c PEKING UNIVERSITY THIRD HOSPITAL   (China)

Author keywords

Diagnosis; Intraoperative complications; Malignant hyperthermia

Indexed keywords

BICARBONATE; ETOMIDATE; FENTANYL; FUROSEMIDE; ISOFLURANE; MIDAZOLAM; MYOGLOBIN; NITROUS OXIDE; OXYGEN; PROCAINE; PROPOFOL; REMIFENTANIL; SUXAMETHONIUM; VECURONIUM; CAFFEINE; HALOTHANE;

ARTERIAL OXYGEN SATURATION; ARTICLE; AXILLA TEMPERATURE; CAFFEINE HALOTHANE CONTRACTURE TEST; CASE REPORT; CHINESE; CLINICAL FEATURE; COMA; CREATINE KINASE BLOOD LEVEL; DIAGNOSTIC TEST; DIAGNOSTIC VALUE; DRUG WITHDRAWAL; END TIDAL CARBON DIOXIDE TENSION; FATALITY; FEMALE; GENERAL ANESTHESIA; HUMAN; HYPERCAPNIA; INDUCED HYPOTHERMIA; INTENSIVE CARE; MALIGNANT HYPERTHERMIA; MANDIBLE RECONSTRUCTION; MOUTH TEMPERATURE; MUSCLE RIGIDITY; QUADRICEPS FEMORIS MUSCLE; RATING SCALE; SCOLIOSIS; THERAPEUTIC HYPERVENTILATION; TONSILLECTOMY; ADOLESCENT; ADULT; CHILD; CHINA; DIAGNOSTIC USE; DRUG EFFECTS; IN VITRO STUDY; MALE; MUSCLE CONTRACTION; YOUNG ADULT;

ADOLESCENT; ADULT; CAFFEINE; CHILD; CHINA; FEMALE; HALOTHANE; HUMANS; IN VITRO TECHNIQUES; MALE; MALIGNANT HYPERTHERMIA; MUSCLE CONTRACTION; YOUNG ADULT;

EID: 77952937746     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2010.10.002     Document Type: Article

References (22)

1. McCarthy EJ. Malignant hyperthermia: pathophysiology, clinical presentation, and treatment. AACN Clin Issues 2004; 15: 231-237.
2. Halliday NJ. Malignant hyperthermia. J Craniofac Surg 2003; 14: 800-802.
3. The European Malignant Hyperpyrexia Group. A protocol for the investigation of malignant hyperpyrexia (MH) susceptibility. Br J Anaesth 1984; 56: 1267-1269.
4. Larach MG. Standardization of the caffeine halothane muscle contracture test: North American Malignant Hyperthermia Group. Anesth Analg 1989; 69: 511-515.
5. Islander G, Twetman ER. Comparison between the European and North American protocols for diagnosis of malignant hyperthermia susceptibility in humans. Anesth Analg 1999; 88: 1155-1160.
6. Allen GC, Larach MG, Kunselman AR. The sensitivity and specificity of the caffeine-halothane contracture test: a report from the North American Malignant Hyperthermia Registry. The North American Malignant Hyperthermia Registry of MHAUS. Anesthesiology 1998; 88: 579-588.
7. Bendahan D, Guis S, Monnier N, Kozak-Ribbens G, Lunardi J, Ghattas B, et al. Comparative analysis of in vitro contracture tests with ryanodine and a combination of ryanodine with either halothane or caffeine: a comparative investigation in malignant hyperthermia. Acta Anaesthesiol Scand 2004; 48: 1019-1027.
8. Ording H, Brancadoro V, Cozzolino S, Ellis FR, Glauber V, Gonano EF, et al. In vitro contracture test for diagnosis of malignant hyperthermia following the protocol of the European MH Group: results of testing patients surviving fulminant MH and unrelated low-risk subjects-the European Malignant Hyperthermia Group. Acta Anaesthesiol Scand 1997; 41: 955-966.
9. Ording H, Islander G, Bendixen D, Ranklev-Twetman E. Between-center variability of results of the in vitro contracture test for malignant hyperthermia susceptibility. Anesth Analg 2000; 91: 452-457.
10. Snoeck MM, Gielen MJ, Tangerman A, Van Egmond J, Dirksen R. Contractures in skeletal muscle of malignant hyperthermia susceptible patients after in vitro exposure to sevoflurane. Acta Anaesthesiol Scand 2000; 44: 334-337.
11. Carr AS, Lerman J, Cunliffe M, McLeod ME, Britt BA. Incidence of malignant hyperthermia reactions in 2214 patients undergoing muscle biopsy. Can J Anaesth 1995; 42: 281-286.
12. Melton AT, Antognini JF, Gronert GA. Caffeine- or halothane-induced contractures of masseter muscle are similar to those of vastus muscle in normal humans. Acta Anaesthesiol Scand 1999; 43: 764-769.
13. Isaacs H, Badenhorst M. False-negative results with muscle caffeine halothane contracture testing for malignant hyperthermia. Anesthesiology 1993; 79: 5-9.
14. MacKenzie AE, Allen G, Lahey D, Crossan ML, Nolan K, Mettler G, et al. A comparison of the caffeine halothane muscle contracture test with the molecular genetic diagnosis of malignant hyperthermia. Anesthesiology 1991; 73: 4-8.
15. Islander G, Ranklev-Twetman E. Evaluation of anaesthesia in malignant hyperthermia negative patients. Acta Anaesthesiol Scand 1995; 39: 819-821.
16. Larach MG, Localio AR, Allen GC, Denborough MA, Ellis FR, Gronert GA,et al. A clinical grading scale to predict malignant hyperthermia susceptibility. Anesthesiology 1994; 80: 771-779.
17. Litman RS, Rosenberg H. Malignant hyperthermia: update on susceptibility testing. JAMA 2005; 293: 2918-2924.
18. Wedel DJ, Nelson TE. Malignant hyperthermia: diagnostic dilemma-false-negative contracture responses with halothane and caffeine alone. Anesth Analg 1994; 78: 787-792.
19. Christiaens F, Gepts E, D'Haese J, Camu F. Malignant hyperthermia suggestive hypermetabolic syndrome at emergence from anesthesia. Acta Anaesthesiol Belg 1995; 46: 93-97.
20. Wang YL, Guo XY, Luo AL. Analysis of literature reports on malignant hyperthermia in mainland China. Chin J Anesthesiol (Chin) 2006; 26: 107-109.
21. Wang YL, Guo XY, Xu ZH, Huang YG, Luo AL. Application of caffeine-halothane contracture test in the diagnosis of malignant hyperthermia. Acta Academic Med Sinica (Chin) 2008; 30: 182-186.
22. Xu ZH, Luo AL, Guo XY, Ren HZ, Wang YL, Zhang X, et al. Malignant hyperthermia in China. Anesth Analg 2006; 103: 983-985.